Inno4Vac is an interdisciplinary project with the objective to harness advances in immunology, big data and artificial intelligence, 3D tissue models and human infection models, so that they can be incorporated into the vaccine industry to accelerate the development of new vaccines. Inno4Vac is funded by the Innovative Medicines Initiative 2 (IMI2), and gathers global leaders in the fields of clinical research, immunology, microbiology, systems biology, mathematical models, and regulatory matters.

The ultimate goal of the project is to develop more predictive biological and mathematical models of vaccine performance, so that vaccine development becomes faster and more efficient.


  • Enhancing understanding of immune response to disease, host-pathogen interactions, vaccine MoA and associated contribution of several factors on immunobiology;
  • Increasing likelihood of CHIM incorporation into vaccine-development initiatives on a wider scale;
  • Increasing likelihood of incorporation of next-generation, versatile in vitro models & assays into vaccine-development initiatives on a wider scale;
  • Potentially replacing animal testing in vaccine research, licensure and release by next generation in vitro models and assays in the future;
  • Improving understanding of how scale-up and scale-down transitions affect manufacturing of vaccines and can be modulated to safeguard vaccine quality and stability/shelf-life;
  • Increasing efficiency of vaccine-manufacturing processes allowing affordable development of vaccines for small/targeted populations; personalized vaccines or sustainable development of vaccines for disease in LIMCs.

The project is running from September 1, 2021 until February 28, 2027 and is coordinated by European Vaccine Initiative (EVI).

To read more about Inno4VAC, you can visit their website: